Malignant tumors following renal transplantation

Patient survival time following renal and other solid organ transplantation has been increasing recently, in part due to modern immunosuppressive regimens. However, the probability of malignant tumor formation is also increasing proportionally to survival time, as a side effect of long-term immunosu...

Full description

Saved in:
Bibliographic Details
Published inOrvosi hetilap Vol. 148; no. 45; p. 2115
Main Authors Végso, Gyula, Járay, Jeno
Format Journal Article
LanguageHungarian
Published Hungary 11.11.2007
Subjects
Adrenal Cortex Hormones - adverse effects
Azathioprine - adverse effects
Calcineurin Inhibitors
Cyclosporine - adverse effects
Humans
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - adverse effects
Incidence
Kidney Transplantation
Lymphoproliferative Disorders - etiology
Muromonab-CD3 - adverse effects
Neoplasms - epidemiology
Neoplasms - etiology
Neoplasms - prevention & control
Neoplasms - therapy
Neoplasms - virology
Prognosis
Sarcoma, Kaposi - etiology
Skin Neoplasms - etiology
Tacrolimus - adverse effects
Online AccessGet more information

Cover

More Information
Summary:Patient survival time following renal and other solid organ transplantation has been increasing recently, in part due to modern immunosuppressive regimens. However, the probability of malignant tumor formation is also increasing proportionally to survival time, as a side effect of long-term immunosuppression. The primary factor of increased tumor risk is the deficient antitumoral and antiviral function of the immune system. The frequency of posttransplantation tumors is 2 to 4-fold compared to the non-transplanted population, and the distribution of tumor types is also different. The most frequent tumor types--skin cancer, lymphoma, Kaposi's sarcoma, oral cancer, anogenital tumors, etc.--are often associated with oncogenic viruses. Treatment options and the prognosis of posttransplant tumors are worse than in the normal population. The increasing frequency of posttransplantation tumors is an important factor determining the long-term fate of transplant patients. The reduction of carcinogenic agents, the early diagnosis and treatment of tumors and precancerous conditions, low dose immunosuppression and the usage of immunosuppressive agents with an oncologically favorable, anti-proliferative effect will help reduce the risk of posttransplant tumor formation.
ISSN:0030-6002